Carregant...

Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

Clinical trials aiming to develop disease-altering drugs for Alzheimer’s disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of objective biomarkers, is one of the major conc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Declercq, Lieven D., Vandenberghe, Rik, Van Laere, Koen, Verbruggen, Alfons, Bormans, Guy
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4814730/
https://ncbi.nlm.nih.gov/pubmed/27065872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00088
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!